Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Mueller V, Woeckel A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Hadji P, Tesch H, Ettl J, Lueftner D, Welslau M, Belleville E, Brucker SY, Schuetz F, Fasching P, Fehm TN, Kolberg HC, Schneeweiss A, Overkamp F (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 78
Pages Range: 1119-1128
Journal Issue: 11
DOI: 10.1055/a-0715-2899
Abstract
New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments.
Authors with CRIS profile
Naiba Nabieva
Department of Obstetrics and Gynaecology
Peter Fasching
Professur für Translationale Frauenheilkunde und Geburtshilfe
Involved external institutions
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Krankenhaus Nordwest
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Klinikum Aschaffenburg
Germany (DE)
ClinSol GmbH & Co.KG
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Marienhospital Bottrop
Germany (DE)
OncoConsult
Germany (DE)
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Krankenhaus Nordwest
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
Technische Universität München (TUM)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Klinikum Aschaffenburg
Germany (DE)
ClinSol GmbH & Co.KG
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
Marienhospital Bottrop
Germany (DE)
OncoConsult
Germany (DE)
How to cite
APA:
Mueller, V., Woeckel, A., Lux, M.P., Janni, W., Hartkopf, A.D., Nabieva, N.,... Overkamp, F. (2018). Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe und Frauenheilkunde, 78(11), 1119-1128. https://doi.org/10.1055/a-0715-2899
MLA:
Mueller, Volkmar, et al. "Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer." Geburtshilfe und Frauenheilkunde 78.11 (2018): 1119-1128.
BibTeX: Download